57 results about "Immunodeficiency virus" patented technology

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody pair for detecting cat immunodeficiency virus p24 protein and application of the monoclonal antibody pair. The monoclonal antibody pair is a monoclonal antibody 1D8 and a monoclonal antibody 1H10 and can specifically recognize cat immunodeficiency virus p24 protein, and sequences of complementary determining regions of variable regions of a heavy chain and a light chain of the 1D8 and the 1H10 are clear and are respectively shown as SEQ ID NO.1-12. The antibody pair can effectively avoid cross reaction, and the accuracy and sensitivity of detection are remarkably improved; the colloidal gold test strip constructed on the basis of the antibody pair is simple, convenient and rapid to operate, is suitable for early antigen detection of FIV infection, solves the problem that natural infection and vaccine immunity cannot be distinguished in existing antibody detection, and provides a reliable technical means for FIV field screening and disease prevention and control.

The present disclosure relates to pharmaceutical compositions comprising an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The Human Immunodeficiency Virus (HIV) infection and recurrent infection prevention mRNA vaccine comprising epitopes of HIV-1 and HIV-2 viruses and their corresponding Nef proteins.

The Human Immunodeficiency Virus (HIV) infection and recurrent infection prevention mRNA vaccine comprising epitopes of HIV-1 and HIV-2 viruses and their corresponding Nef proteins.

This disclosure relates to a method for preparing intermediates useful for preparing compounds that inhibit the function of human immunodeficiency virus (HIV) during the viral replication cycle, such as by disrupting the function of the HIV capsid shell. [Formula 1] JPEG2026524821000058.jpg39145

This invention provides a wide range of neutralizing antibodies targeting the epitopes of human immunodeficiency virus (HVM) or HIV. Furthermore, it provides compositions containing antibodies for use in prevention, and methods for the diagnosis and treatment of HIV infection. [Solution] An isolated anti-HIV antibody or its antigen-binding fragment is provided, comprising a heavy chain variable region containing a specific sequence and a light chain variable region containing a specific sequence. The antibody is a recombinant antibody or a human antibody.

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

The invention relates to the field of biological detection, in particular to a broad-spectrum specific antibody and application thereof. The invention provides a monoclonal antibody of human immunodeficiency virus P24 protein. Three CDR regions of a heavy chain of the monoclonal antibody respectively have amino acid sequences shown as SEQ ID NO: 3, 4 and 5; the three CDR regions of the light chain of the gene respectively have amino acid sequences as shown in SEQ ID NO: 7, 8 and 9. A recombinant human immunodeficiency virus P24 protein is used as an immunogen, a monoclonal antibody capable of simultaneously detecting HIV-1 and HIV-2 core proteins P24 is successfully prepared through different multi-type antigen sequential immunization strategies, an epitope interval of the monoclonal antibody is determined through a recombinant P24 fragment, and a foundation is laid for establishing a detection kit with higher sensitivity.

The present invention relates to processes for preparing intermediates useful in the preparation of compounds that inhibit human immunodeficiency virus (HIV) function (e.g., disrupt HIV capsid function) during the viral replication cycle.

Peptides generating antibodies to human immunodeficiency virus (HIV) post-infection were identified. Higher antibody reactivity to these peptides was associated, with lower viral load post-infection.

The present disclosure relates to monoclonal human antibodies, or binding fragments thereof, directed against the CD4 binding site of human immunodeficiency virus HIV-1, pharmaceutical compositions comprising such monoclonal human antibodies, or binding fragments thereof, kits comprising such antibodies, or binding fragments thereof, and monoclonal antibodies or binding fragments thereof as well as pharmaceutical compositions and kits for use as medicaments and for the treatment or prevention of diseases caused by human immunodeficiency virus HIV-1.

The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and / or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.

Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins of the MPER region of gp140 as well as having a CD4 domain that binds to the CD4bs of gp120.

Provided herein are a vector for eradicating human immunodeficiency virus (HIV) from a human comprising a nucleic acid sequence encoding a dual-function protein that inhibits infectious HIV from budding from HIV-infected cells and represses replication of the vector in the absence of HIV. Methods of treating of HIV and kits are also provided.

Disclosed is a compound of formula (I): for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.

The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods useful for elimination of human immunodeficiency virus-1 (HIV-1) reservoir cells. In several embodiments, the single chain diabody binds human immunodeficiency virus 1 Envelope protein variable loops 1 and 2 (HIV-1 Env V1 / V2) and human type III Fcγ receptor (CD16). In a specific embodiment, the scDb comprises (a) an anti-HIV-1 Env V1 / V2 antigen binding fragment comprising a VH comprising or consisting of SEQ ID NO:1; (b) an anti-HIV Env V1 / V2 antigen binding fragment comprising a VL comprising or consisting of SEQ ID NO:5; (c) an anti-CD16 antigen binding fragment comprising a VH comprising or consisting of SEQ ID NO:17; and (d) an anti-CD16 antigen binding fragment comprising a VL comprising or consisting of SEQ ID NO:21.

In the present invention, the applicant provides a novel method of prophylactically or therapeutically treating acquired immunodeficiency syndrome (AIDS) in a subject in need thereof, where the subject is a human immunodeficiency virus (HIV) serum positive patient. Applicant also provides a novel method of preventing acquired immunodeficiency syndrome (AIDS) in a subject in need thereof, wherein the subject is a human immunodeficiency virus (HIV) serum negative patient. Applicant also provides a novel method of prophylactic or therapeutic treatment of acquired immunodeficiency syndrome (AIDS) in a subject in need thereof, wherein the subject is an elite controller patient that is serum positive for human immunodeficiency virus (HIV).

Provided herein are methods, diagnostic instruments, and kits for detecting the presence or absence of an analyte associated with a disease in a subject. In some embodiments, the disease is Lyme disease, SARS-CoV-2, or a human immunodeficiency virus infection.

This disclosure is directed to pharmaceutical compositions and methods for treating or preventing HIV infection in a subject in need thereof. The composition can comprise an adenosine derivative that can be administered via injection, oral intake, implant, or a combination thereof.

The invention relates to the field of bioengineering, and discloses a human immunodeficiency virus p24 antigen and antibody detection kit and a preparation method thereof. The kit comprises a colloidal gold marker composite pad, wherein the colloidal gold marker composite pad comprises a p24 antibody colloidal gold marker, an HIV antigen colloidal gold marker and a chicken IgY antibody colloidal gold marker; an AG line, an AB line and a C line are arranged on the NC membrane, the AG line is coated with a p24 monoclonal antibody, the AB line is coated with HIV-I, HIV-II and HIV-O mixed antigens, and the C line is coated with goat anti-chicken IgY; and a sample pad, a conjugate pad and a water absorbent pad. The human immunodeficiency virus p24 antigen and antibody detection kit provided by the invention is obviously superior to the prior art in the aspects of sensitivity, specificity, convenience and stability, and has important clinical application and market values.

The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable liquid vehicle. Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) in a human, including administering to the human a pharmaceutical composition disclosed herein.

The present invention relates to monoclonal human antibodies or binding fragments thereof directed against the V3 glycan site of human immunodeficiency virus HIV-1, pharmaceutical compositions comprising such monoclonal human antibodies or binding fragments thereof, kits comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, and pharmaceutical compositions comprising such antibodies or binding fragments thereof. And monoclonal antibodies or binding fragments thereof as well as pharmaceutical compositions and kits for use as medicaments and for the treatment or prevention of diseases caused by human immunodeficiency virus HIV-1.

Provided are a pharmaceutically acceptable salt, a crystal form and a preparation method of a TLR7 / 8 agonist compound of formula I, a pharmaceutical composition containing the pharmaceutically acceptable salt, and a medical use of the pharmaceutically acceptable salt, which can be used for preparing drugs for preventing or treating Toll-like receptor 7 / 8 (TLR7 / 8) related diseases, such as a new therapeutic agent for human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and cancer.

The present disclosure relates to vaccine compositions against respiratory syncytial virus (RSV) that are tomato-based and their methods of production. The vaccine compositions comprise tomato fruit and plant-expressed fragment of RSV F protein, preferably the ectodomain of the RSV F protein. In some aspects, the vaccine compositions comprise tomato fruit and plant-expressed human immunodeficiency virus (HIV) virus-like particle (VLP) wherein the fragment of RSV F protein is displayed on the VLP surface. For example, the vaccine compositions are tomato paste spiked with the plant-expressed HIV VLP. In certain embodiments, the plant-expressed HIV VLP comprises a Gag protein; a fragment of gp41 protein, which comprises the C-terminal cytosolic domain of the gp41 protein; and a fragment of RSV F protein, wherein the fragment of RSV F protein lacks the p27 region and the C-terminus of the fragment of RSV F protein is linked to the N-terminus of the fragment of gp41 protein.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The invention provides a novel isoxazolopyrimidine derivative, a pharmaceutical composition and application of the novel isoxazolopyrimidine derivative, and belongs to the technical field of medicine synthesis. The novel isoxazolopyrimidine derivative provided by the invention can be used in drugs for inhibiting human immunodeficiency virus activity. The targeted drug inhibits interaction between the virus capsid protein and the host factor CPSF6, prevents nuclear input in HIV-1 virus infection and a transcriptional activation region positioning process, and achieves an efficient antiviral effect.

Provided herein are a vector for eradicating human immunodeficiency virus (HIV) from a human comprising a nucleic acid sequence encoding a dual-function protein that inhibits infectious HIV from budding from HIV-infected cells and represses replication of the vector in the absence of HIV. Methods of treating of HIV and kits are also provided.

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I):including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

The invention encompasses the activation of PIEZO proteins for therapeutic application in treatment and cure of disease. An example of this inventive activation is a method of using a PIEZO-type mechanosensitive ion channel component 1 (PIEZO1) agonist, such as Yoda1, as a latency reversal agent (LRA) in human immunodeficiency virus type-1 (HIV-1) infection.